• I-BET-762: From BET Binding to Ferroptosis

  2026-08-26

  I-BET-762 is a selective BET inhibitor that connects chromatin-reader biology with ferroptosis, inflammation, and cancer biology research. This mechanism-first guide explains how to design and interpret assays without confusing BET-family effects with BRD4-specific mechanisms.

• Azathramycin A: Mtb Ribosome Research Guide

  2026-08-25

  Azathramycin A is a macrolide antibiotic and ribosome-binding research compound directed toward Mycobacterium tuberculosis protein synthesis. This guide distinguishes its documented biochemical rationale, product handling parameters, degradation chemistry, and research limitations from evidence generated with azithromycin itself.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow

  2026-08-25

  Use this Cy3 secondary antibody to convert mouse-primary-based HMGB1 validation into a sensitive, visually resolved assay workflow. Practical guidance covers immunofluorescence, western blotting, flow cytometry, controls, storage, and troubleshooting for biomarker research.

• IR-820 (New Indocyanine Green): From Signal to Strategy

  2026-08-24

  IR-820 (New Indocyanine Green) can serve as more than a near-infrared label: it can become a translational decision layer connecting biodistribution, vascular behavior, tumor localization, and treatment response. This thought-leadership article examines how its imaging properties relate to indocyanine-green-enabled photothermal immunotherapy while separating evidence from the 2023 melanoma study from practical recommendations for validating IR-820 itself.

• Arachidonic Acid and Rapid Vaccine Immunity

  2026-08-23

  The reference study identifies dietary arachidonic acid as a potential nutritional adjuvant that accelerates and strengthens rabies vaccine-induced humoral immunity in mice and human volunteers. Its mechanistic contribution is the link between arachidonic acid metabolism in lymph nodes, prostaglandin I2 signaling, and B-cell maturation through the cAMP–PKA pathway.

• Phosbind Acrylamide: Practical SDS-PAGE Guide

  2026-08-22

  Phosbind Acrylamide (SKU F4002) adds a phosphate-binding reagent to SDS-PAGE gel preparation so phosphorylation-dependent mobility differences can be examined without phospho-specific antibodies. It is most appropriate for dossier-supported protein targets in the 30–130 kDa range and should not be treated as a site-specific phosphorylation assay or a substitute for protein identity confirmation.

• Hepatic sEH–Nrf2 Axis in Osteoporosis

  2026-08-21

  A study in Free Radical Biology and Medicine identifies a liver–bone signaling axis in which hepatic soluble epoxide hydrolase alters circulating epoxide metabolites, suppresses Nrf2-ARE activity, and promotes osteoclast differentiation. By combining patient samples, an ovariectomy-induced mouse model, liver-specific knockdown, pharmacological inhibition, and transcriptomics, the work provides a mechanistic framework for understanding redox imbalance in osteoporosis.

• Viral RIPK3 Degradation and Proteasome-Driven Inflammation

  2026-08-20

  Liu et al. identified a family of orthopoxvirus proteins, termed viral inducers of RIPK3 degradation, that recruit host SCF machinery to promote RIPK3 ubiquitination and proteasomal destruction. The study connects this immune-evasion mechanism to necroptosis, viral replication, inflammation, and mortality in vivo, providing a framework for dissecting ubiquitin-proteasome control of host–pathogen interactions.

• Y-27632 ROCK Inhibitor: Organoid Workflow Guide

  2026-08-20

  Y-27632 enables controlled ROCK1 and ROCK2 inhibition for linking cell shape, adhesion, and stress-fiber behavior to epithelial repair assays. This guide translates a recent Treg–intestinal epithelium study into practical organoid, monolayer, and cytoskeletal workflows while separating validated findings from experimental extensions.

• Ruxolitinib, DRP1, and ATC Cell Death

  2026-08-19

  The 2024 Cell Death and Disease study identifies a previously underappreciated connection between JAK1/2-STAT3 signaling, DRP1-dependent mitochondrial fission, and regulated cell death in anaplastic thyroid carcinoma. Its in vitro and in vivo evidence indicates that ruxolitinib can promote caspase-dependent apoptosis and GSDME-mediated pyroptosis by suppressing STAT3-driven DRP1 transcription.

• Losmapimod Workflow for p38 MAPK Research

  2026-08-19

  Build reproducible inflammation, endothelial, and dephosphorylation assays around Losmapimod, also known as GW856553X. This practical guide connects selective p38α/p38β inhibition with dose design, vascular readouts, WIP1-oriented mechanistic testing, and troubleshooting.

• GOB-38 in Elizabethkingia anophelis: Study Insights

  2026-08-18

  The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, using recombinant expression, purified-enzyme analysis, genomic investigation, and bacterial co-culture. Its broad hydrolysis profile and distinctive active-site residues help explain resistance phenotypes while highlighting why biochemical measurements must be interpreted alongside genomic and transmission evidence.

• Olaparib and the Next Layer of PARP Biology

  2026-08-18

  Olaparib (AZD2281, Ku-0059436) is more than a PARP-1/2 inhibitor for BRCA-deficient models. This thought-leadership guide connects DNA damage response assays, PAR-dependent condensate biology, and tumor radiosensitization studies to help translational researchers design more informative cancer research workflows.

• Vitamin C in HEV Organoid Assay Design

  2026-08-17

  Vitamin C and ascorbic acid can be evaluated more rigorously in hepatitis E virus organoids by separating antiviral activity from tissue toxicity. This article translates a multilineage HEV model into a practical, hypothesis-driven assay framework for cancer research and antiviral discovery.

• Formononetin Protects Neurons During Oxaliplatin Therapy

  2026-08-17

  A 2026 NeuroToxicology study identifies formononetin as a candidate for reducing oxaliplatin-induced peripheral neurotoxicity through Nrf2/HO-1 antioxidant signaling while preserving anticancer activity. Its selective activity, including limited protection against paclitaxel-related neurite damage, highlights both the promise and the boundaries of pathway-focused neuroprotection.

454 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page